Integrated Diagnostics

What Integrated Diagnostics does

Integrated Diagnostics is a Seattle-based, privately held molecular diagnostics company founded in 2005 that develops non-invasive blood-based tests intended to help physicians diagnose complex diseases. The company was co-founded by Leroy Hood, Jim Heath, and David Galas — figures associated with the Institute for Systems Biology and the broader systems-biology movement in the Pacific Northwest — which situates the firm within the proteomic and multi-analyte diagnostics tradition rather than single-biomarker testing. The company's functional proposition is to provide clinicians with blood-based diagnostic information that would otherwise require more invasive procedures or extended workups for complex conditions.

Across roughly two decades, Integrated Diagnostics has raised an aggregate of approximately $95M across multiple venture rounds from a syndicate of life-sciences-focused investors, including ARCH Venture Partners, MPM Capital, Versant Ventures, OVP Venture Partners, Amgen Ventures, Alexandria Real Estate Equities, InterWest Partners, Wellcome Trust, Baird Capital, and Life Sciences Alternative Funding. The company maintains a small operating footprint of 11-50 employees and operates from Seattle, Washington. Its current commercial model, pricing structure, distribution channels, and specific product names are not disclosed in the available source material, and no revenue figures have been publicly reported. As of March 31, 2026, Elliott Investment Management disclosed a 21.67% ownership stake, making it a significant minority shareholder.

Operationally, the company appears to be in an early-commercial or pre-commercial stage: its last disclosed funding round was a $6.1M Series 3 in December 2016, and no subsequent financing activity is evidenced in the input data. Leadership is led by Chairman David L. Barker, with Steven Springmeyer serving as Chief Medical Officer and Doug Fisher as Senior VP of Corporate Development; Jim Heath, David Galas, and Leroy Hood continue to serve as co-founders on the board. The combined profile — elite scientific founders, a long-dated venture-backed structure, a substantial activist-investor stake, and limited disclosed commercial metrics — paints the picture of a science-led diagnostics asset whose commercialization trajectory remains unproven.

Name

Integrated Diagnostics

Website

https://indidx.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

Integrated Diagnostics is a Seattle-based molecular diagnostics company developing non-invasive blood-based tests to help physicians diagnose complex diseases. Founded in 2005, it operates with 11-50 employees and is backed by approximately $95M in venture funding.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

akta.pro secondary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

• Molecular diagnostics
• Blood-based diagnostics
• Non-invasive disease testing
• Clinical diagnostic tools
• Biomarker analysis

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Core offering

Integrated Diagnostics develops non-invasive blood-based diagnostic tests intended to help physicians diagnose complex diseases. The company's core focus is on creating clinically actionable diagnostic tools that reduce the need for invasive procedures and improve the accuracy and speed of complex disease diagnosis.

Differentiator

Problem solved

Functional benefit

Products and services

• Non-Invasive Blood-Based Diagnostic Tests A blood test designed to help physicians diagnose complex diseases non-invasively, intended as an alternative to invasive biopsy or imaging-based diagnostic methods.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves6 records

Expansion highlights3 records

Broad incumbents

• Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling of tumors. It is a broad incumbent offering molecular diagnostic solutions for complex cancer cases, comparable to InDi's positioning in advanced disease diagnostics.
• Bio-Techne: Bio-Techne manufactures reagents, proteins, and diagnostic tools used in biomarker discovery and clinical diagnostics. It is a broad incumbent providing enabling technologies and assays in the same proteomic/molecular diagnostic ecosystem as InDi.
• Quest Diagnostics: Quest Diagnostics is a large reference laboratory offering a broad menu of blood-based diagnostic tests, including advanced specialty diagnostics. It is a broad incumbent competing for the same physician-ordered blood diagnostic workflows that InDi targets.
• Exact Sciences: Exact Sciences is a scaled diagnostics company with Cologuard (stool-based) and Oncotype DX, expanding into blood-based cancer detection. It is a broad incumbent in molecular diagnostics targeting similar clinical use cases as InDi's blood tests.

Direct peers

• Adaptive Biotechnologies: Adaptive Biotechnologies applies immune repertoire sequencing to develop blood-based diagnostics for disease detection and immune monitoring. It overlaps with InDi in using blood-based molecular approaches to address complex disease diagnosis.
• Natera: Natera provides blood-based molecular diagnostics, including cell-free DNA tests for oncology, transplant monitoring, and reproductive health. It is comparable to InDi as a developer of non-invasive blood-based diagnostic tests for complex clinical questions.
• GRAIL: GRAIL develops blood tests for early cancer detection using methylation-based sequencing. Like InDi, it pursues non-invasive blood-based diagnostics for complex diseases (multi-cancer early detection), making it a directly comparable peer in technology and clinical positioning.
• Guardant Health: Guardant Health is a leading blood-based liquid biopsy company focused on cancer diagnostics using cell-free DNA. It directly competes with InDi in the blood-based complex-disease diagnostic space, targeting oncology indications through non-invasive blood tests.

Emerging players

• Cardio Diagnostics: Cardio Diagnostics develops AI-driven blood-based epigenetic and genetic tests for cardiovascular disease. As an emerging player in blood-based molecular diagnostics for complex disease, it parallels InDi's technology approach and clinical positioning.
• Personalis: Personalis is a cancer genomics company developing blood- and tissue-based molecular diagnostics. It overlaps with InDi in using advanced molecular approaches to characterize complex disease states for clinical decision-making.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/integrateddx
• Facebookfacebook.com/411565118853541
• LinkedInlinkedin.com/company/integrated-diagnostics

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Integrated Diagnostics